Kelly Chibale

Dr. Kelly Chibale is a distinguished Professor of Medicinal Chemistry at the University of Cape Town's Faculty of Health Sciences, where he directs the Drug Discovery and Development Centre (H3D). His global collaborations span the South African Medical Research Council, University of Cambridge, Scripps Research Institute, and University of Zambia, establishing him as a leading figure in African drug discovery.

Chibale's research pioneers the integration of artificial intelligence and machine learning in virtual screening for infectious disease therapeutics, with primary focus on malaria and tuberculosis. His work bridges computational methodologies with experimental validation to develop novel antiparasitic and antibacterial compounds, emphasizing practical solutions for resource-limited settings through collaborative science frameworks.

His publication record reveals consistent innovation in antitubercular and antiplasmodial drug development, characterized by rigorous structure-activity relationship studies, target identification, and ADME characterization. Recent work demonstrates sophisticated approaches to overcoming drug resistance while optimizing pharmacokinetic properties.

Research funding is secured through major international sponsors including the National Institutes of Health (24.9%), National Research Foundation (21.8%), and National Institute of Allergy and Infectious Diseases (9.4%), reflecting the global significance of his work in infectious disease therapeutics.

As founder of Africa's first integrated drug discovery center (H3D), Chibale has built a multidisciplinary team advancing capacity building in medicinal chemistry across the continent, with satellite operations in Zambia and strategic partnerships spanning Europe, Asia, and North America.